Biopsy of breast cancer metastases: patient characteristics and survival
Open Access
- 4 January 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 7
Abstract
Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010–2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.Keywords
This publication has 23 references indexed in Scilit:
- Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and MetastasisThe Oncologist, 2013
- Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkersCritical Reviews in Oncology/Hematology, 2012
- Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studiesCancer Treatment Reviews, 2012
- Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast CancerJournal of Clinical Oncology, 2012
- Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)Breast Cancer Research, 2010
- Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and MetastasisThe Oncologist, 2010
- Receptor conversion in distant breast cancer metastasesBreast Cancer Research, 2010
- Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2004
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- The variability of estrogen receptors in metastatic breast cancerThe American Journal of Surgery, 1979